Disease Specific Programme News Today

This new analysis on IBD patients initiating biologic therapy with the biosimilar ABP 501 indicates that the drug’s lower cost and efficacy may lead to greater use.

Data presented at ASN Kidney Week 2023 highlighted the patient-reported difficulty of implementing physician-recommended lifestyle changes but noted significant impacts on physical health, mental health, and overall quality of life when done successfully.

/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two abstracts on amyotrophic lateral sclerosis (ALS) will be presented...